Business

ReCode Therapeutics announced that it has raised $50 million as an extension to a Series B financing, with funds going toward clinical development of its inhaled mRNA therapies for the treatment of primary ciliary dyskinesia and cystic fibrosis. The company says that it has now raised a total of $260 million in Series B funding. ReCode CEO Shehnaaz Suliman … [Read more...] about ReCode Therapeutics announces additional funding for development of its inhaled mRNA therapies

The Western Australian Future Health Research and Innovation Fund has awarded a A$499,241 Innovation Seed Fund grant to Virex Pharma for development of Glyxine, an inhaled antiviral nanoemulsion, for the treatment of respiratory syncytial virus. According to Virex, the grant will go toward testing of Glyxine in epithelial cells and in animal models of RSV at Wal-yan … [Read more...] about Virex gets almost A$500,000 grant for development of GlyXine inhaled antiviral

Virpax Pharmaceuticals announced that it has spun off a wholly-owned subsidiary called Novvae Pharmaceuticals that will develop Virpax's over-the-counter products, starting with AnQlar antiviral nasal spray. Virpax acquired North American rights to AnQlar, which contains a mucoadhesive polymer derived from chitosan, from Nanomerics in August 2020 and expanded the deal … [Read more...] about Virpax spins off Novvae Pharmaceuticals to develop AnQlar nasal spray

According to Evoke Pharma, the company has received a notice of allowance from the US Patent and Trademark Office (USPTO) for patent application No. 17/366,829 ("Nasal Formulations of Metoclopramide"). The patent will cover the composition of Evoke's Gimoti intranasal metoclopramide, which was approved by the FDA in June 2020 for the treatment of diabetic … [Read more...] about Evoke Pharma gets notice of allowance for new US patent covering Gimoti metoclopramide nasal spray

Oxford Science Enterprises and Harrington Discovery Institute at University Hospitals, together with the University of Edinburgh’s Old College Capital venture investment fund, have created a startup called AlveoGene to develop inhaled gene therapies based on a lentivirus platform technology licensed from the UK Respiratory Gene Therapy Consortium (GTC). The new … [Read more...] about Startup AlveoGene to develop inhaled gene therapies

According to Orexo, the United States Patent and Trademark Office (USPTO) has issued the company US patent No. 11,737,980 ("Pharmaceutical composition for drug delivery") which provides protection for OX640 epinephrine nasal powder. Orexo notes that it also received a European patent covering OX640 in 2022. The company announced Phase 1 results for OX640 in October … [Read more...] about Orexo gets US patent related to its OX640 intranasal dry powder epinephrine

Lupin has launched its generic version of Spiriva HandiHaler tiotropium bromide DPI for the treatment of COPD in the US, the company said. The FDA approved Lupin's ANDA for the tiotropium bromide inhaler in June 2023. The generic of Spiriva HandiHaler was recently approved in Australia and has also been approved in the UK and Canada. Lupin CEO Vinita Gupta … [Read more...] about Lupin launches its generic tiotropium bromide DPI in the US

Trudhesa dihydroergotamine (DHE) nasal spray maker Impel Pharmaceuticals (formerly Impel Neuropharma) has filed a document with the US Securities and Exchange Commission stating that it "has concluded that there is substantial doubt about the Company’s ability to continue as a going concern." Earlier this year, Impel announced that it needed to "streamline" and would … [Read more...] about Impel Pharmaceuticals says that it may need to sell assets or enter bankruptcy